Galectin Therapeutic (GALT)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Fiscal Year End Date: 12/31
(Values in U.S. thousands)
| 12-2024 | 12-2023 | 12-2022 | 12-2021 | 12-2020 | |
| Assets | |||||
| Current Assets | |||||
| Cash & Cash Equivalents | 15,120 | 25,660 | 18,592 | 39,648 | 27,142 |
| TOTAL | $17,252 | $27,710 | $20,552 | $41,820 | $29,465 |
| Non-Current Assets | |||||
| Other Non-Current Assets | 243 | 490 | 733 | 7 | 135 |
| TOTAL | $243 | $490 | $733 | $7 | $135 |
| Total Assets | $17,495 | $28,200 | $21,285 | $41,827 | $29,600 |
| Liabilities | |||||
| Current Liabilities | |||||
| Accounts payable and accrued liabilities | 5,656 | 6,431 | 3,890 | 1,805 | 1,292 |
| Accrued Expenses | 8,204 | 9,182 | 9,058 | 7,163 | 4,042 |
| Other current liabilities | 369 | N/A | N/A | N/A | N/A |
| TOTAL | $35,409 | $15,676 | $13,012 | $9,033 | $5,399 |
| Non-Current Liabilities | |||||
| Other Non-Current Liabilities | 85,156 | 72,765 | 40,467 | 30,178 | 8 |
| TOTAL | $85,156 | $72,765 | $40,467 | $30,178 | $8 |
| Total Liabilities | $120,565 | $88,441 | $53,479 | $39,211 | $5,407 |
| Shareholders' Equity | |||||
| Shares Outstanding, K | 63,180 | 61,904 | 59,444 | 59,358 | 57,156 |
| Common Shares | 62 | 61 | 59 | 59 | 56 |
| Retained earnings | -401,572 | -354,372 | -309,567 | -270,694 | -239,996 |
| Other shareholders' equity | 2,223 | 2,223 | 2,233 | 2,250 | 2,250 |
| TOTAL | $-103,070 | $-60,241 | $-32,194 | $2,616 | $24,193 |
| Total Liabilities And Equity | $17,495 | $28,200 | $21,285 | $41,827 | $29,600 |